Multiple Staphylococcus aureus antigens (S. aureus antigens)

Staphylococcus aureus is a versatile Gram-positive pathogen that utilizes an extensive repertoire of virulence factors to colonize hosts and cause disease, ranging from skin infections to life-threatening bacteremia (Tong et al., 2015, Clin Microbiol Rev). The concept of Multiple Staphylococcus aureus antigens involves targeting a combination of these factors—such as surface adhesins (Clumping factor A), nutrient acquisition proteins (IsdB), and secreted toxins (Alpha-hemolysin)—to create effective vaccines or monoclonal antibody therapies (Fowler et al., 2013, JAMA). These antigens are essential for the bacteria's ability to adhere to host tissues, evade the immune system, and acquire essential metals like iron. Because S. aureus possesses redundant mechanisms for pathogenesis, single-antigen approaches have largely failed in clinical trials, leading researchers to focus on multi-component formulations like Pfizer's SA4Ag or Aridis Pharmaceuticals' AR-301 (Clegg et al., 2021, Vaccines). These therapies work by inducing neutralizing antibodies that prevent toxin-mediated cell damage or by promoting opsonophagocytic killing of the bacteria. However, the high genetic diversity of S. aureus strains and the lack of clear correlates of protection remain significant hurdles in the development of these multi-antigen products (Proctor, 2012, Front Cell Infect Microbiol).

Other names

Staphylococcus aureus surface proteinsStaphylococcal toxinsS. aureus vaccine targetsStaphylococcal antigens

Induction of opsonophagocytic and neutralizing antibodies to inhibit bacterial adhesion, nutrient uptake, and toxin-mediated host cell lysis.